Physician profile
James H Johnson
NPI 1699762666
$1,758.43
in general payments reported to CMS, 2019-2025
24 companies · $453 in 2025
The $453 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $211 · 2021: $327 · 2022: $154 · 2023: $199 · 2024: $242 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $893.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $495.31 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $197.36 | 2020-2021 | |
| Astellas Pharma US INC | $135.57 | 2019-2024 | Veozah |
| Abbott Laboratories | $115.13 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.27 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $90.34 | 2024 | Farxiga, Airsupra |
| Pfizer INC. | $66.95 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $65.92 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Novartis Pharmaceuticals Corporation | $64.32 | 2019-2025 | |
| Lilly USA, LLC | $51.32 | 2023-2025 | Mounjaro, Trulicity, Zepbound |
| Otsuka America Pharmaceutical, INC. | $47.72 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $47.49 | 2022-2025 | Shingrix, Arexvy |
| Edwards Lifesciences Corporation | $36.51 | 2020 | |
| Amgen INC. | $36.42 | 2019-2024 | Otezla, Repatha |
| Abbvie INC. | $35.18 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $28.81 | 2025 | |
| Medline Industries LP | $19.69 | 2025 | |
| Idorsia Pharmaceuticals US INC | $18.03 | 2023 | Quviviq |
| Xeris Pharmaceuticals, INC. | $17.05 | 2022 | |
| Philips North America LLC | $15.77 | 2024 | (Cm9) Amb Mon & Diag Und |
| Rti Surgical, INC | $15.51 | 2023 | |
| Sanofi-Aventis U.S. LLC | $15.37 | 2022 | |
| Esperion Therapeutics, INC. | $15.23 | 2022 | |
| Radius Health, INC. | $13.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.